Cipla Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wfpawmo9tseergtay6ecaho1.pdf

Key Takeaways


US Business: The Structural Shift

Vohra: "A large number of US companies are either amalgamating, merging, or are going bankrupt. That is eliminating certain number of people in the system. It's also having an impact on certain channels in the US, which only buy products which are made domestically. So we are seeing a rebalancing of the supply chain happening, because of which, our base families are actually growing."

India Business: Market-Beating Growth

Vohra: "We are very excited about that business because that's a business which we realize that more people want to stay well longer than they are sick."

Complex Pipeline & Facility Derisking

Vohra: "Beyond this year if Indore is not cleared, yes, but not beyond FY '25."

South Africa & International Markets


Margins & Investment


Guidance & Commitments

CommitmentSpecificsTimeline
US base business run-rateUSD 210–215 mn per quarter; will flag any fall-offOngoing, quarter-by-quarter
Full-year EBITDA marginTrending toward 23%FY24
Generic Advair launchProduct to market with no incremental generic competition expectedWithin 12 months
Generic Abraxane dual-site supplyAbility to supply from both current and CMO sitesBy FY25
Symbicort filingFiled with USFDABy end of CY23
Peptide launches4–5 launches; a couple of new peptides filedNext two years
India rep additions500 net additions, then pauseBy Q2 FY24
Capex4–5% of revenue, INR 1,000–1,500 crore p.a.Annual

Key Metrics

MetricQ1 FY24
Revenue₹6,329 cr, +18% YoY
EBITDA margin23.6% (reported, excluding other income), includes higher R&D and provisions
Gross margin64.7%, +230 bps YoY, driven by new launches and mix change
Profit after tax₹996 cr, 15.7% of sales
Effective tax rate27.5%, constant YoY
R&D investment₹349 cr, 5.5% of revenue, +27% YoY
Total expenses₹2,598 cr, +3.8% QoQ
Net cash position₹6,138 cr, improved from ₹5,469 cr in March
Full-year EBITDA guidance~23%, raised from 22%
US business revenue$222 mn (USD22.2 cr), +43% YoY, highest ever
US base business quarterly run-rate$210–215 mn (USD21–21.5 cr), up from $190–200 mn last quarter
India branded prescriptions growthSignificantly higher than IPM growth (MAT June '23)
India chronic therapies revenue share60%, up from 58% YoY; industry market share improved from 8.4% to 8.6%
Foracort growth27% YoY, one of the fastest in top 10 IPM brands
South Africa private market growth13% YoY in local currency; OTC portfolio grew 16%
South Africa market positionSecond largest player in prescription market by market share
Lanreotide US market share18% as per MAT May '23
India MR net additions250–300 added in Q1; targeting 500 net additions by Q2
Consumer health revenue~₹385 cr, roughly 14% of total revenue
Capex guidance4–5% of revenue, ₹1,000–1,500 cr per annum, roughly 50-50 maintenance vs growth